Back
#1
17.9%
Top 1%
14.8%
Top 1%
7.9%
Top 12%
7.9%
Top 71%
6.5%
Top 63%
4.2%
Top 1%
3.9%
Top 12%
3.9%
Top 6%
2.8%
Top 2%
2.8%
Top 2%
2.0%
Top 5%
1.6%
Top 1%
1.6%
Top 3%
1.4%
Top 11%
1.4%
Top 8%
1.2%
Top 1%
1.0%
Top 67%
0.7%
Top 13%
0.7%
Top 7%
0.7%
Top 2%
0.7%
Top 10%
0.7%
Top 7%
0.7%
A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in Cancer
2025-04-04
oncology
Title + abstract only
View on medRxiv
Show abstract
PurposeAPX3330 is an oral agent targeting the redox signaling activity of Ape1/Ref-1 (Ref-1), a key regulator of transcription factors involved in inflammation and tumorigenesis. APX3330 selectively inhibits Ref-1s redox function without affecting its DNA repair role. This Phase 1, multicenter, open-label, dose-escalation study in advanced solid tumor was aimed at determining the recommended Phase 2 dose (RP2D) while assessing safety, pharmacokinetics, and biomarker evidence of target engagement...
Predicted journal destinations
1
Clinical Cancer Research
22 training papers
2
Cancers
57 training papers
3
Frontiers in Oncology
34 training papers
4
Nature Communications
483 training papers
5
PLOS ONE
1737 training papers
6
Scientific Reports
701 training papers
7
Cancer Medicine
17 training papers
8
eLife
262 training papers
9
JAMA Network Open
125 training papers
10
British Journal of Cancer
22 training papers
11
BMC Cancer
21 training papers
12
Nature Medicine
88 training papers
13
Science Translational Medicine
40 training papers
14
Journal of Clinical Investigation
50 training papers
15
Proceedings of the National Academy of Sciences
100 training papers
16
iScience
74 training papers
17
Cell Reports
25 training papers
18
BMJ Open
553 training papers
19
Frontiers in Immunology
140 training papers
20
International Journal of Molecular Sciences
39 training papers
21
International Journal of Cancer
18 training papers
22
Nature
58 training papers
23
Cell Reports Medicine
49 training papers